Latest Breaking News On - Acute graft versus host disease - Page 1 : comparemela.com

Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesLin changRegion flamandeNew yorkJulie khlevnerChristopherv almarioKishorer iyerGerard greigLos angelesAstrid verbiestCenter trialUniversity of leuvenCedars sinai medical centerExchange commissionDrug administrationTranslational research center

STARS: Apraglutide Reduces Parenteral Support in Patients with Stoma, Colon-In-Continuity

New STARS data were presented in a late-breaking abstract at DDW and build upon positive topline results for clinical responder rates and reductions in parenteral support.

District of columbiaUnited statesMichael shetzlineKishore iyerIronwood pharmaceuticalsDrug administrationMount sinaiDigestive disease weekMount sinai hospitalNew drug applicationAcute graft versus host disease

Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024

– Data from pivotal Phase III STARS study in short bowel syndrome with intestinal failure accepted as late-breaker oral presentation on May 21 at 10:30 am ET – – Findings from the STARS.

United statesMichael shetzlineIronwood pharmaceuticals nasdaqExchange commissionA national survey analysisIronwood pharmaceuticalsIronwood pharmaceuticals incCenter trialDrug administrationDisease weekApraglutide once weeklyShort bowel syndromeIntestinal failureGlobal phasePlacebo controlled trialBowel morphology

Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)

Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesMichael shetzlineRobert zeiserIronwood pharmaceuticalsInternational consortiumExchange commissionUniversity of freiburgIronwood pharmaceuticals nasdaqIronwood pharmaceuticals incHead of researchGraft versus host diseaseMount sinai acutePrincipal investigatorSenior vice presidentChief medical officerAcute graft versus host disease

Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesMichael shetzlineBeth calitriGreg martiniMatt roacheKishorer iyerIronwood pharmaceuticals incIronwood pharmaceuticals nasdaqIronwood pharmaceuticalsExchange commissionPediatric intestine rehabilitationMount sinai hospitalCoordinating principal investigatorShort bowel syndromeAcute graft versus host disease